RLFTF (Relief Therapeutics Holding) Additional Paid-In Capital : $296.95 Mil(As of Dec. 2024)

View and export this data going back to 1990. Start your Free Trial

What is Relief Therapeutics Holding Additional Paid-In Capital?

Relief Therapeutics Holding's quarterly additional paid-in capital declined from Dec. 2023 ($247.66 Mil) to Jun. 2024 ($0.00 Mil) but then increased from Jun. 2024 ($0.00 Mil) to Dec. 2024 ($296.95 Mil).

Relief Therapeutics Holding's annual additional paid-in capital increased from Dec. 2022 ($231.52 Mil) to Dec. 2023 ($247.66 Mil) and increased from Dec. 2023 ($247.66 Mil) to Dec. 2024 ($296.95 Mil).

Relief Therapeutics Holding Additional Paid-In Capital Historical Data

The historical data trend for Relief Therapeutics Holding's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Additional Paid-In Capital Chart

Relief Therapeutics Holding Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

77.16

225.32

231.52

247.66

296.95

Relief Therapeutics Holding Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Additional Paid-In Capital	Get a 7-Day Free Trial															231.52	-	247.66	-	296.95

Relief Therapeutics Holding Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Relief Therapeutics Holding Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Relief Therapeutics Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

RLFTY:USA RLFz:UK 0QKQ:UK RLF:Switzerland

Address

Avenue de Secheron 15, Geneva, CHE, 1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.